Skip to main content
. Author manuscript; available in PMC: 2019 Feb 12.
Published in final edited form as: Mol Omics. 2018 Feb 12;14(1):26–36. doi: 10.1039/c7mo00006e

Figure 1.

Figure 1

Binding mode of pyrrolo[3,4-c]pyrazol inhibitors. a) Binding mode typical for type I kinase inhibitors, including the interactions with the hinge region and the hydrophobic pockets I and II. b) Co-crystal structure of PHA-680632 and the HsAURKA catalytic domain. Ribbon color indicates the type of secondary structure; red = α-helix, yellow = β-sheet, white = disordered.24 PDBID: 2J50.